Notice of Results

ABZENA PLC

("Abzena", the "Company" or the "Group")

Notice of Interim Results

2 December 2014

Cambridge, UK - Abzena plc (AIM: ABZA), the life sciences company providing services and technologies that enable the development of better biopharmaceutical products, will announce its interim results for the six months ended 30 September 2014 on Thursday 11 December 2014.

John Burt, CEO of Abzena, and Julian Smith, CFO, will host a presentation for analysts at 9:00am on the morning of the results at the offices of Citigate Dewe Rogerson, 3 London Wall Buildings, London Wall, London EC2M 5SY.

About Abzena

Abzena provides proprietary technologies and value-added services to enable the development of better biopharmaceuticals.

Abzena comprises two wholly owned subsidiary businesses - PolyTherics and Antitope - which have established a broad suite of complementary technologies that are designed to improve the chances of successful development of antibodies and proteins with enhanced therapeutic benefits.

Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and manufacturing cell line development.

PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimization of the therapeutic properties of biopharmaceuticals.

The Group has built a global customer base over the past decade, including the top 10 pharma, large and small biotech, and academic groups.

Abzena is listed on the AIM segment of the London Stock Exchange under the symbol ABZA.

www.abzena.com 

For more information, please contact:

John Burt (Chief Executive Officer)

Julian Smith (Chief Financial Officer)

Abzena plc

Tel: +44 (0)1223 903498

Email: [email protected] or [email protected]

Christopher Golden and Bobbie Hilliam

Cenkos Securities (Nominated Adviser and Broker)

Tel: +44 (0)20 7397 8900

Mark Swallow, Sita Taylor or Chris Gardner

Citigate Dewe Rogerson (Corporate and Financial PR)

Tel: +44 (0)20 7638 9571

Email: [email protected]